Targeting other abnormal signaling pathways in sarcoma: EGFR in synovial sarcomas, PPAR-gamma in liposarcomas.
Blay
Jean-Yves
JY
Unité d'Oncologie Médicale, Hôpital Edouard Herriot, Place d'Arsonval, 69003 Lyon.
Ray-Coquard
Isabelle
I
Alberti
Laurent
L
Ranchère
Dominique
D
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D066246:ErbB Receptors / Q000378:metabolism*; D006801:Humans; D008080:Liposarcoma / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015514:Oncogene Proteins, Fusion / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000378:metabolism*; D013584:Sarcoma, Synovial / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D015398:Signal Transduction / Q000187:drug effects*; D014157:Transcription Factors / Q000378:metabolism*
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D015514:Oncogene Proteins, Fusion; D018160:Receptors, Cytoplasmic and Nuclear; D014157:Transcription Factors; D066246:ErbB Receptors